BioSpace News Archive

BioMidwest

Calyxt Announces Agreement with Evologic Technologies to Scale Production of its Plant-based Ingredients

Calyxt, Inc. announced that it has signed an agreement with its first manufacturing partner, Evologic Technologies GmbH, to further develop and scale Calyxt’s proprietary Plant Cell Matrix™ technology platform.

October 6, 2022
·
6 min read
Evogene to Present at the LD Micro Main Event XV Investor Conference in Los Angeles

Evogene Ltd. announced today that Ofer Haviv , Evogene’s President and CEO, will attend and present at LD Micro Main Event taking place from Tuesday, October 25 to Wednesday, October 26, 2022, in Los Angeles.

October 6, 2022
·
2 min read
Business

EpicentRx Announces First Patient Dosed in China for the Phase 3 REPLATINUM Global Study with RRx-001 in Third Line and Beyond Extensive Stage Small Cell Lung Cancer (SCLC)

EpicentRx announced today the start of dosing in China for the global Phase 3 clinical trial REPLATINUM (NCT05566041) with partner SciClone Pharmaceuticals.

October 6, 2022
·
3 min read
Business

CytoSorbents Awarded an Approximately $4.3M Contract by the U.S. Department of Defense to Develop HemoDefend-BGA™ for Freeze-Dried Universal Plasma

CytoSorbents Corporation announced today that the U.S. Army Medical Research Acquisition Activity (USAMRAA) has awarded the Company a three-year Phase III contract valued at $4,292,641 to customize the design of the HemoDefend-BGA™ filter for sterile integration into collections systems for freeze-dried plasma processing to generate freeze-dried universal plasma.

October 6, 2022
·
8 min read
FDA

Boston Cell Standards Wins First-Ever FDA 510(k) Clearance for Anatomic Pathology Controls

FDA clearance introduces first immunohistochemistry IHControls panel for evaluating breast cancers.

October 6, 2022
·
3 min read
Business

Revelation Biosciences Inc. and Vanderbilt University Enter Exclusive Worldwide License Agreement

Revelation Biosciences Inc. today announced an exclusive worldwide license agreement with Vanderbilt University, Nashville TN, USA (Vanderbilt) to develop and commercialize phosphorylated hexaacyl disaccharide (PHAD), for treating or preventing infections.

October 6, 2022
·
5 min read
Business

Sanofi US enters into co-promotion agreement with Provention Bio, Inc. to launch teplizumab, an investigational disease-modifying therapy for type 1 diabetes

Sanofi US to co-promote teplizumab, adding it to its current commercial activities in diabetes care, leveraging its existing best-in-class customer-facing field teams Provention Bio, Inc. retains all rights to teplizumab Commercialization activities are dependent on U.S. FDA approval of teplizumab, potentially on November 17, 2022.

October 6, 2022
·
6 min read
Business

AngioDynamics Reports Fiscal 2023 First Quarter Financial Results; Reaffirms Guidance

AngioDynamics, Inc. today announced financial results for the first quarter of fiscal year 2023, which ended August 31, 2022.

October 6, 2022
·
15 min read
Business

Medexus Announces Preliminary Revenue Results for Second Fiscal Quarter 2023Quarterly revenue expected to exceed US$27.0 million for quarter ended September 30, 2022, an all-time record

Medexus Pharmaceuticals ( Medexus ) (TSX: MDP) (OTCQX: MEDXF) is pleased to announce preliminary estimates of the company’s revenue results for the fiscal quarter ended September 30, 2022 (the company’s fiscal Q2 2023).

October 6, 2022
·
8 min read
Genetown

Phio Pharmaceuticals Announces Upcoming Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Phio Pharmaceuticals Corp. today announced it is scheduled to provide an update on its programs at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held in Boston, MA from November 8 - 12, 2022.

October 6, 2022
·
5 min read